Dr. Muhammet AVCİL

Dr. Muhammet Avcil is a Turkish scientist, entrepreneur, and academic leader specializing in biotechnology, drug discovery, and translational research. He has an extensive international academic and entrepreneurial background and serves in strategic research and clinical development roles at Biruni University and Biruni University Hospital.

Early Life and Education
Dr. Avcil showed entrepreneurial initiative from a young age, starting his first business at age 11 by selling figs to contribute to his family’s income. Driven by a commitment to education and science, he pursued higher education abroad, completing advanced degrees in molecular design, drug discovery, and related fields at respected universities in the United Kingdom.

Academic and Research Career
He completed multiple graduate and doctoral programs focused on molecular design and cancer drug development, achieving exceptional academic performance by completing his doctoral work ahead of schedule and undertaking additional research projects. During his doctoral training and subsequent postdoctoral activities, he worked closely with academic mentors and research groups in molecular and pharmaceutical sciences, contributing to innovative research in drug delivery and therapeutics.

Entrepreneurship and Biotechnology Leadership
In 2016, Dr. Avcil founded Imperial BioScience, a biotechnology company focused on developing next-generation therapeutics and dermocosmetic solutions. Under his leadership, the company’s first product, “Eternal,” achieved significant market penetration in over 16 countries, with strong early sales and commercial adoption. His entrepreneurial ventures also include Luna MicroCare and Biruni Cell Therapy, demonstrating his commitment to translating scientific innovation into real-world products and therapies.

Role at Biruni University and Clinical Research Initiatives
At Biruni University, Dr. Avcil contributes to the institution’s research strategy, clinical trial frameworks, and translational research activities. He has played a leading role in establishing and expanding clinical research infrastructure, including the Biruni University Hospital Phase 1 Clinical Research Center, which supports early-phase human studies and collaborates with industry partners to advance therapeutic development.

Scientific Contributions and Impact
Dr. Avcil is an author of multiple peer-reviewed research articles, particularly in drug delivery systems and clinical applications of microneedle technologies. He maintains active collaborations with international research communities to advance evidence-based biomedical innovation.

Vision and Leadership
His vision emphasizes bridging academic research, biotechnology entrepreneurship, and clinical application. Under his guidance, research teams pursue translational approaches that aim to convert scientific discoveries into impactful health solutions and innovative therapies.

Professional Affiliations and Mentorship
Beyond institutional leadership, Dr. Avcil actively supports educational programs, internships, and mentorship for emerging scientists and clinicians, fostering the next generation of innovators in biomedical science and biotechnology entrepreneurship.